ORYN THERAPEUTICS, Inc.

ORYN THERAPEUTICS, Inc. is a clinical-stage company specializing in the development of Orynotides, a new class of drug candidates. These proprietary cyclic peptides are engineered to be stable, with low immunogenicity and toxicity. They demonstrate effectiveness in modulating pathologic inflammation and have shown promise in treating conditions such as rheumatoid arthritis, ulcerative colitis, and certain cancers. Founded in 2008, Oryn Therapeutics operates within the Biotechnology and Health Care sectors. The company's focus on addressing unmet medical needs through its innovative drug candidates makes it an attractive prospect for venture capital investment. Oryn Therapeutics' advancements in modulating inflammation and enhancing host defense against drug-resistant pathogens position it at the forefront of cutting-edge medical research. As the company continues to progress through clinical trials and make strides in drug development, it presents an opportunity for investors to participate in the potential success of novel treatment solutions.